Memantine/donepezil

Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type.^[1] It contains memantine hydrochloride (it acts as an NMDA receptor antagonist, among various other types of targets like 5-HT3 receptor, Nicotinic acetylcholine receptor, and Sigma-1 receptor) and donepezil hydrochloride, which is an acetylcholinesterase inhibitor.^[1] It is taken by mouth.^[1]

Memantine/donepezil

Combination of
Memantine	NMDA receptor antagonist
Donepezil	Acetylcholinesterase inhibitor
Clinical data
Trade names	Namzaric
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Memantine and donepezil
Routes of administration	By mouth
ATC code	N06DA52 (WHO)
Legal status
Legal status	US: ℞-only[1] Rx-only[2]
Identifiers
KEGG	D11387

Memantine/donepezil was approved for medical use in the United States in 2014.^[3]